bioAffinity Technologies Inc. (BIAF)
NASDAQ: BIAFHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BIAF stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.00M
- EPS (TTM)
- -$40.37
- Dividend yield
- None
- 52-week range
- 1.63 – 80.70
- Day range
- 1.63 – 1.84
- Volume / Avg
- 52.64K / 3.55M
- Beta
- —
- Shares outstanding
- 1.82M
52-week range
BIAF stock today
Shares of bioAffinity Technologies (BIAF) finished lower on Nov 20 at $1.65, a drop of 10.81% or $0.20 per share, versus the S&P 500's 3.70% decline. Trading was light, with 52.64K shares changing hands, about 1% of the average daily volume. At this level, BIAF sits near the bottom of its 52-week range of $1.63 to $80.70: 98.0% below the high and 1.2% above the low.
bioAffinity Technologies has posted a net loss over the last twelve months (EPS of -$40.37), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About bioAffinity Technologies
Company profilebioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services.
- Sector
- Health Care
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- CEO
- Ms. Maria Zannes J.D.
- Headquarters
- San Antonio, TX
- Employees
- 57
- IPO year
- 2022
- Website
- bioaffinitytech.com
Financial highlights
Full financialsIn fiscal 2025, bioAffinity Technologies generated $6.2 million in revenue, down 34.2% from fiscal 2024, the first decline in the 5 years shown. bioAffinity Technologies reported a net loss of $14.9 million, compared with a loss of $9.0 million a year earlier. Operating margin was -171.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $6.16M | $9.36M | $7.90M | $6.90M | — |
| Growth | -34.18% | +18.51% | +14.49% | — | — |
| Net income | $-14.91M | $-9.04M | $-7.94M | $-8.15M | $-6.33M |
| EPS (diluted) | $-8.66 | $-22.50 | $-0.91 | $-1.81 | — |
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 13, 2026
- EPS actual vs est.
- $-5.89 vs —
BIAF news
All BIAF news- bioAffinity Technologies, Inc. Reports Results of Special Meeting and Amendment to Certificate of IncorporationNasdaq
- bioAffinity Technologies, Inc. Reports 109% Increase in CyPath Lung Test Unit Sales and Record October VolumeNasdaqBIAF, UHAL.B
- bioAffinity Technologies Reports Third Quarter 2026 ResultsNasdaq
- bioAffinity Technologies Reports Third Quarter 2026 Results and Continued Momentum in CyPath® Lung CommercializationBusiness Wire
- WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq RulesPR Newswire
- WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq RulesPR Newswire
bioAffinity Technologies peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ISPCiSpecimen Inc. | 0.4563 | -13.58% | $2.64M | vs BIAF |
| ONMDOneMedNet Corp Class A | 4.70 | +4.21% | $29.15M | vs BIAF |
| MXCTMaxCyte Inc. | 1.37 | +7.03% | $141.45M | vs BIAF |
| NRCNRC Health | 25.16 | +0.68% | $533.93M | vs BIAF |
| OABIOmniAb Inc. | 4.66 | -7.36% | $679.71M | vs BIAF |
| ABSIAbsci Corporation | 7.51 | -7.97% | $1.30B | vs BIAF |
| ICLRICON plc | 186.71 | -1.92% | $13.99B | vs BIAF |
| CRLCharles River Laboratories International Inc. | 314.32 | -4.15% | $15.06B | vs BIAF |
Indexes, lists and sector
bioAffinity Technologies stock FAQ
What is bioAffinity Technologies's stock price today?
BIAF last traded at $1.65 as of Nov 20, 4:00 PM EST, down 10.81% on the day. Prices are delayed at least 15 minutes.
Who is bioAffinity Technologies's CEO?
Ms. Maria Zannes J.D. is the chief executive officer of bioAffinity Technologies Inc., which has about 57 employees.
What is the BIAF 52-week high?
The 52-week high for BIAF is $80.70 and the 52-week low is $1.63. The stock is currently 98.0% below its high.